SALT LAKE CITY, UT — They make be working in a state famous for its long underwear and complex alcohol regulations, but researchers at the University of Utah are well along the path to helping women, their fetuses, and newborns avoid the scourge of AIDS.”We have developed a new vaginal gel that we call a molecular condom, because it is composed of molecules that are liquid at room temperature and, when applied in the vagina, will spread and turn into a gel and effectively coat the tissue,” assistant professor of bioengineering Patrick Kiser explains. “It’s a smart molecular condom, because we designed this gel to release anti-HIV drugs when the gel comes into contact with semen during intercourse.”
According to Kiser, the goal of the new technology is to protect women and their fetuses from the AIDS virus. Additionally, the molecular condom will extend protection also to nursing infants.
The molecular condom is part of an international effort to develop effective gels, rings, sponges, or creams which deliver anti-HIV and other STD medication into the system via “microbicides.” The University of Utah molecular condom consists of a repeating, chain-like structure called a polymer and made from three chemicals: N-isopropylacrylamide, butyl methacrylate, and acrylic acid.
“The three together,” Kiser explains,” have the property of liquid at room temperature and vaginal pH, solid at body temperature and vaginal pH, and liquid at body temperature and semen pH.”
Unfortunately, especially for women in AIDS ravaged Africa and India, the molecular condom is five years from human tests and a decade away from distribution.
More information about the development of the molecular condom can be found online in the Monday, December 11th issue of the Journal of Pharmaceutical Sciences Subscription to the site is a requirement for viewing its contents.
